F-18-Flutemetamol Amyloid Imaging in Alzheimer Disease and Mild Cognitive Impairment A Phase 2 Trial
(2010) In Annals of Neurology 68(3). p.319-329- Abstract
- Objective: The most widely studied positron emission tomography ligand for in vivo P-amyloid imaging is C-11-Pittsburgh compound B (C-11-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the F-18-labeled PIB derivative F-18-flutemetamol could significantly enhance access to this novel technology. Methods: Twenty-seven patients with early-stage clinically probable Alzheimer disease (AD), 20 with amnestic mild cognitive impairment (MCI), and 15 cognitively intact healthy volunteers (HVs) above and 10 HVs below 55 years of age participated. The primary endpoint was the efficacy of blinded visual assessments of F-18-flutemetamol scans in assigning subjects to a raised versus normal uptake category,... (More)
- Objective: The most widely studied positron emission tomography ligand for in vivo P-amyloid imaging is C-11-Pittsburgh compound B (C-11-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the F-18-labeled PIB derivative F-18-flutemetamol could significantly enhance access to this novel technology. Methods: Twenty-seven patients with early-stage clinically probable Alzheimer disease (AD), 20 with amnestic mild cognitive impairment (MCI), and 15 cognitively intact healthy volunteers (HVs) above and 10 HVs below 55 years of age participated. The primary endpoint was the efficacy of blinded visual assessments of F-18-flutemetamol scans in assigning subjects to a raised versus normal uptake category, with clinical diagnosis as the standard of truth (SOT). As secondary objectives, we determined the correlation between the regional standardized uptake value ratios (SUVRs) for F-18-flutemetamol and its parent molecule C-11-PIB in 20 of the AD subjects and 20 of the MCI patients. We also determined test-retest variability of F-18-flutemetamol SUVRs in 5 of the AD subjects. Results: Blinded visual assessments of F-18-flutemetamol scans assigned 25 of 27 scans from AD subjects and 1 of 15 scans from the elderly HVs to the raised category, corresponding to a sensitivity of 93.1% and a specificity of 93.3% against the SOT. Correlation coefficients between cortical F-18-flutemetamol SUVRs and C-11-PIB SUVRs ranged from 0.89 to 0.92. Test-retest variabilities of regional SUVRs were 1 to 4%. Interpretation: F-18-Flutemetamol performs similarly to the C-11-PIB parent molecule within the same subjects and provides high test-retest replicability and potentially much wider accessibility for clinical and research use. ANN NEUROL 2010;68:319-329 (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1672533
- author
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of Neurology
- volume
- 68
- issue
- 3
- pages
- 319 - 329
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000281421800012
- scopus:77956384880
- pmid:20687209
- ISSN
- 1531-8249
- DOI
- 10.1002/ana.22068
- language
- English
- LU publication?
- yes
- id
- b123ba6a-431c-4bbc-8061-ce6bcac6840a (old id 1672533)
- date added to LUP
- 2016-04-01 10:09:46
- date last changed
- 2022-05-17 20:24:13
@article{b123ba6a-431c-4bbc-8061-ce6bcac6840a,
abstract = {{Objective: The most widely studied positron emission tomography ligand for in vivo P-amyloid imaging is C-11-Pittsburgh compound B (C-11-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the F-18-labeled PIB derivative F-18-flutemetamol could significantly enhance access to this novel technology. Methods: Twenty-seven patients with early-stage clinically probable Alzheimer disease (AD), 20 with amnestic mild cognitive impairment (MCI), and 15 cognitively intact healthy volunteers (HVs) above and 10 HVs below 55 years of age participated. The primary endpoint was the efficacy of blinded visual assessments of F-18-flutemetamol scans in assigning subjects to a raised versus normal uptake category, with clinical diagnosis as the standard of truth (SOT). As secondary objectives, we determined the correlation between the regional standardized uptake value ratios (SUVRs) for F-18-flutemetamol and its parent molecule C-11-PIB in 20 of the AD subjects and 20 of the MCI patients. We also determined test-retest variability of F-18-flutemetamol SUVRs in 5 of the AD subjects. Results: Blinded visual assessments of F-18-flutemetamol scans assigned 25 of 27 scans from AD subjects and 1 of 15 scans from the elderly HVs to the raised category, corresponding to a sensitivity of 93.1% and a specificity of 93.3% against the SOT. Correlation coefficients between cortical F-18-flutemetamol SUVRs and C-11-PIB SUVRs ranged from 0.89 to 0.92. Test-retest variabilities of regional SUVRs were 1 to 4%. Interpretation: F-18-Flutemetamol performs similarly to the C-11-PIB parent molecule within the same subjects and provides high test-retest replicability and potentially much wider accessibility for clinical and research use. ANN NEUROL 2010;68:319-329}},
author = {{Vandenberghe, Rik and Van Laere, Koen and Ivanoiu, Adrian and Salmon, Eric and Bastin, Christine and Triau, Eric and Hasselbalch, Steen and Law, Ian and Andersen, Allan and Korner, Alex and Minthon, Lennart and Garraux, Gaetan and Nelissen, Natalie and Bormans, Guy and Buckley, Chris and Owenius, Rikard and Thurfjell, Lennart and Farrar, Gill and Brooks, David J.}},
issn = {{1531-8249}},
language = {{eng}},
number = {{3}},
pages = {{319--329}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Annals of Neurology}},
title = {{F-18-Flutemetamol Amyloid Imaging in Alzheimer Disease and Mild Cognitive Impairment A Phase 2 Trial}},
url = {{http://dx.doi.org/10.1002/ana.22068}},
doi = {{10.1002/ana.22068}},
volume = {{68}},
year = {{2010}},
}